DrugPatentWatch

DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices.

Patent: 4,939,130

Summary for Patent: 4,939,130

Title: Substituted alkanediphosphonic acids and pharmaceutical use
Abstract:Alkanediphosphonic acids, in particular heteroarylalkanediphosphonic acids of formula ##STR1## wherein R.sub.1 is a 5-membered heteroaryl radical which may be fused with benzene or cyclohexene nuclei and which contains, as hetero atoms, 2 to 4 N-atoms or 1 or 2 N-atoms as well as 1 O- or S-atom, and which is unsubstituted or C-substituted by lower alkyl, phenyl or phenyl which is substituted by lower alkyl, lower alkoxy and/or halogen, or by lower alkoxy, hydroxy, di-lower alkylamino, lower alkylthio and/or halogen, and/or is N-substituted at a N-atom which is capable of substitution by lower alkyl, lower alkoxy and/or halogen, and R.sub.2 is hydrogen, hydroxy, amino, lower alkylthio or halogen, and salts thereof, have regulatory action on calcium metabolism and can be used as medicaments for the treatment of diseases associated with impairment of calcium metabolism. The compounds are obtained for example by converting, in a compound of formula ##STR2## wherein X.sub.1 is a functionally modified phosphono group and X.sub.2 is a free or functionally modified phosphono group, X.sub.1 and, if appropriate X.sub.2, into the free phosphono group.
Inventor(s): Jaeggi; Knut A. (Basel, CH), Widler; Leo (Muchenstein, CH)
Assignee: Ciba-Geigy Corporation (Ardsley, NY)
Application Number:07/315,962
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Compound; Composition; Use;
Patent PDF download available with subscription

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist_Flag Patent Expiration Patented / Exclusive Use
Novartis
ZOMETA
zoledronic acid
INJECTABLE; IV (INFUSION)021223Aug 20, 2001DISCNNo4,939,130*PEDY<disabled>
Novartis
ZOMETA
zoledronic acid
INJECTABLE; IV (INFUSION)021223Mar 7, 2003RXYes4,939,130*PEDY<disabled>
Novartis
ZOMETA
zoledronic acid
INJECTABLE; IV (INFUSION)021223Jun 17, 2011RXYes4,939,130*PEDY<disabled>
Novartis
RECLAST
zoledronic acid
INJECTABLE; IV (INFUSION)021817Apr 16, 2007RXYes4,939,130*PEDY<disabled>
The preview shows a limited data set. Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 4,939,130

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland4666/86Nov 21, 1986

International Patent Family for Patent: 4,939,130

Country Document Number Publication Date
South Africa8708698May 23, 1988
Singapore92194Apr 28, 1995
Portugal86167Dec 01, 1987
Philippines24345Jun 13, 1990
The preview shows a limited data set. Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Sign up for a free trial

First name
Last name
Email address

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639

`abc